|
|||||
|
|
CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver |
|
| Authors: | Adolfo Quiñones‐Lombraña G. Ekin Atilla‐Gokcumen Javier G. Blanco |
| Affiliation: | 1. University at Buffalo, The State University of New York (SUNY), Department of Pharmaceutical Sciences, Buffalo, New York, USA;2. University at Buffalo, The State University of New York (SUNY), Department of Chemistry, Buffalo, New York, USA |
| Abstract: | Loxoprofen is an anti‐inflammatory drug that requires bioactivation into the trans‐OH metabolite to exert pharmacological activity. Evidence suggests that carbonyl reductase 1 (CBR1) is important during the bioactivation of loxoprofen. This study examined the impact of the functional single nucleotide polymorphism CBR1 rs9024 on the bioactivation of loxoprofen in a collection of human liver samples. The synthesis ratios of trans‐OH loxoprofen/cis‐OH loxoprofen were 33% higher in liver cytosols from donors homozygous for the CBR1 rs9024 G allele in comparison with the ratios in samples from donors with heterozygous GA genotypes. Complementary studies examined the impact of CBR1 rs9024 on the bioactivation of loxoprofen in lymphoblastoid cell lines. CBR1 rs9024 genotype status impacts the synthesis of the bioactive trans‐OH metabolite of loxoprofen in human liver. |
| Keywords: | CBR1 CBR1 rs9024 loxoprofen |